ADMA Biologics Inc (ADMA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ADMA Biologics Inc stock (ADMA) is currently trading at $9.63. ADMA Biologics Inc PE ratio is 16.05. ADMA Biologics Inc PS ratio (Price-to-Sales) is 4.50. Analyst consensus price target for ADMA is $25.67. WallStSmart rates ADMA as Hold.
- ADMA PE ratio analysis and historical PE chart
- ADMA PS ratio (Price-to-Sales) history and trend
- ADMA intrinsic value — DCF, Graham Number, EPV models
- ADMA stock price prediction 2025 2026 2027 2028 2029 2030
- ADMA fair value vs current price
- ADMA insider transactions and insider buying
- Is ADMA undervalued or overvalued?
- ADMA Biologics Inc financial analysis — revenue, earnings, cash flow
- ADMA Piotroski F-Score and Altman Z-Score
- ADMA analyst price target and Smart Rating
ADMA Biologics Inc
📊 No data available
Try selecting a different time range
ADMA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · ADMA Biologics Inc (ADMA)
ADMA trades 299% above its Graham fair value of $4.08, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
ADMA Biologics Inc (ADMA) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, profit margin. Concerns around price/book and eps growth. Fundamentals are solid but monitor weak areas for improvement.
ADMA Biologics Inc (ADMA) Key Strengths (5)
Every $100 of shareholder equity generates $36 in profit
Keeps $45 of every $100 in revenue after operating costs
Keeps $29 of every $100 in revenue as net profit
94.88% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
ADMA Biologics Inc (ADMA) Areas to Watch (4)
Earnings declining -52.80%, profits shrinking
Very expensive at 7.2x book value
Premium valuation at 4.5x annual revenue
Solid revenue growth at 18.40% per year
Supporting Valuation Data
ADMA Biologics Inc (ADMA) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 9 metrics analyzed, 5 register as strengths (avg 9.4/10) while 4 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with Return on Equity at 35.60%, Operating Margin at 45.10%, Profit Margin at 28.80%.
The Bear Case
The primary concerns are EPS Growth, Price/Book, Price/Sales. Some valuation metrics including Price/Sales (4.50), Price/Book (7.15) suggest expensive pricing. Growth concerns include Revenue Growth at 18.40%, EPS Growth at -52.80%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 35.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 18.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (EPS Growth, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ADMA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ADMA's Price-to-Sales ratio of 4.50x trades at a deep discount to its historical average of 154.03x (1th percentile). The current valuation is 100% below its historical high of 1787.99x set in Oct 2013, and 11% above its historical low of 4.06x in Jan 2022. Over the past 12 months, the PS ratio has compressed from ~11.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for ADMA Biologics Inc (ADMA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ADMA Biologics Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 510M with 18% growth year-over-year. Profit margins are strong at 28.8%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 35.6% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 28.8% and operating margin of 45.1% demonstrate strong pricing power and operational efficiency.
Earnings fell 53% YoY while revenue grew 18%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ADMA Biologics Inc.
Bottom Line
ADMA Biologics Inc offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ADMA Biologics Inc(ADMA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.